To identify the contribution of individual isoform (α, β, γ, δ) of class I PI3Ks to tumor cell growth for proper use of PI3K inhibitors in cancer therapy. A panel of human rhabdomyosarcoma Rh30 cells ...

Preclinical Results Presented at the American Society of Hematology Annual Meeting SEATTLE, Dec 08, 2008 (BUSINESS WIRE) -- Calistoga Pharmaceuticals, Inc., the leader in the development of ...

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and ...

Targeted therapy with imatinib has transformed the treatment of chronic myeloid leukemia (CML). Unlike CML, chronic lymphocytic leukemia (CLL) lacks a common genetic aberration but does demonstrate ...

Researchers have demonstrated that selective inactivation of the p110&alpha, PI3K isoform is sufficient to block tumor progression and metastasis in a mice model of PanNETs Researchers from the ...

ScienceDaily (Aug. 10, 2010) - Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase (PI3Ks) ...

DUBLIN--(BUSINESS WIRE)--The "Copiktra" report has been added to ResearchAndMarkets.com's offering. Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the ...

Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

Karus Therapeutics is teaming up with the Babraham Institute to further characterize novel treatments for inflammatory diseases. The partners plan to achieve this through the regulation of ...

Researchers from the 'Angiogenesis signaling pathways' research group of the Institute of Biomedical Investigation of Bellvitge (IDIBELL), led by Dr. Mariona Graupera, have unveiled the potential ...